CSPC Pharmaceutical Group Out-Licenses Western Rights For Cancer Drug To Dexcel
5/13/2014 8:16:17 AM
by Richard Daverman, PhD
May 12, 2014 -- CSPC Pharmaceutical Group, headquartered in China's Heibei Province, has partnered with Dexcel Pharma Technologies to co-develop and commercialize a generic oncology drug in the US, Europe and elsewhere. Dexcel is a privately held Israeli generic drug company, with a presence in more than 30 countries. Dexcel will pay CSPC $2 million to defray the pre-clinical and cGMP compliance certification costs. It will also be liable for up to $5 million in milestones, and Dexcel will be responsible for obtaining approvals of the product. More details....
Stock Symbol: (HK: 1093)
Help employers find you! Check out all the jobs and post your resume.
comments powered by